Page 240 - 2021_02-Haematologica-web

P. Cramer et al.
strategies. Blood. 2013;122(23):3723-3734.
17. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
18. Bottcher S, Ritgen M, Kneba M. Flow cyto- metric MRD detection in selected mature B-cell malignancies. Methods Mol Biol. 2013;971:149-174.
19. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitor- ing in chronic lymphocytic leukaemia. Leukemia. 2007;21(5):956-964.
20.Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression- free and overall survival in chronic lympho- cytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988.
21.Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting condi- tions. N Engl J Med. 2014;370(12):1101- 1110.
22. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376 (9747):1164-1174.
23. Eichhorst B, Fink AM, Bahlo J, et al. First- line chemoimmunotherapy with ben- damustine and rituximab versus fludara- bine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocyt-
ic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-infe- riority trial. Lancet Oncol. 2016;17(7):928- 942.
24.Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215- 1228.
32.Wierda WG, Byrd JC, O'Brien S, et al. Tumour debulking and reduction in pre- dicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019;186(1):184-188.
33.Strati P, Sivina M, Kim E, et al. Achievement of complete remission (CR) as an endpoint for patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. J Clin Oncol. 2018;36(15_suppl): 7522.
34. von Tresckow J, Cramer P, Bahlo J, et al. CLL2-BIG: sequential treatment with ben- damustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019;33(5):1161-1172.
35. Cramer P, von Tresckow J, Bahlo J, et al. Durable remissions after discontinuation of combined targeted treatment in patients with chronic lymphocytic leukemia (CLL) harbouring a high-risk genetic lesion (del(17p)/TP53 mutation) Blood. 2018;132 (Suppl 1):694.
36.Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370(24):2286-2294.
37. Woyach JA, Ruppert AS, Guinn D, et al. BTK(C481S)-mediated resistance to ibruti- nib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437-1443.
25.
Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768-778.
26.Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230-240.
27. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311-322.
28.Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497-2506.
29.Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
30. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
31. Cramer P, von Tresckow J, Bahlo J, et al.
554
haematologica | 2021; 106(2)